1. Home
  2. BCDA vs MRIN Comparison

BCDA vs MRIN Comparison

Compare BCDA & MRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • MRIN
  • Stock Information
  • Founded
  • BCDA N/A
  • MRIN 2006
  • Country
  • BCDA United States
  • MRIN United States
  • Employees
  • BCDA N/A
  • MRIN N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • MRIN EDP Services
  • Sector
  • BCDA Health Care
  • MRIN Technology
  • Exchange
  • BCDA Nasdaq
  • MRIN Nasdaq
  • Market Cap
  • BCDA 7.9M
  • MRIN 6.7M
  • IPO Year
  • BCDA N/A
  • MRIN 2013
  • Fundamental
  • Price
  • BCDA $2.84
  • MRIN $1.99
  • Analyst Decision
  • BCDA Strong Buy
  • MRIN
  • Analyst Count
  • BCDA 1
  • MRIN 0
  • Target Price
  • BCDA $25.00
  • MRIN N/A
  • AVG Volume (30 Days)
  • BCDA 58.1K
  • MRIN 19.3K
  • Earning Date
  • BCDA 03-26-2025
  • MRIN 02-28-2025
  • Dividend Yield
  • BCDA N/A
  • MRIN N/A
  • EPS Growth
  • BCDA N/A
  • MRIN N/A
  • EPS
  • BCDA N/A
  • MRIN N/A
  • Revenue
  • BCDA $71,000.00
  • MRIN $16,707,999.00
  • Revenue This Year
  • BCDA N/A
  • MRIN N/A
  • Revenue Next Year
  • BCDA N/A
  • MRIN N/A
  • P/E Ratio
  • BCDA N/A
  • MRIN N/A
  • Revenue Growth
  • BCDA N/A
  • MRIN N/A
  • 52 Week Low
  • BCDA $1.63
  • MRIN $1.44
  • 52 Week High
  • BCDA $8.85
  • MRIN $5.46
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 67.71
  • MRIN 41.94
  • Support Level
  • BCDA $2.27
  • MRIN $1.94
  • Resistance Level
  • BCDA $2.78
  • MRIN $2.19
  • Average True Range (ATR)
  • BCDA 0.26
  • MRIN 0.14
  • MACD
  • BCDA 0.04
  • MRIN -0.00
  • Stochastic Oscillator
  • BCDA 86.90
  • MRIN 9.26

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About MRIN Marin Software Incorporated

Marin Software Inc provides a cloud-based digital advertising management solution for search, display, social, and mobile advertising channels to improve financial performance, realize efficiencies and time savings, and improve business decisions. The company's enterprise marketing software platform is offered as an integrated software-as-a-service (SaaS) solution for advertisers and agencies. Its software solution is designed to help its customers measure the effectiveness of their advertising campaigns through its reporting and analytics capabilities; and manage and execute campaigns through its user interface and underlying technology that streamlines and automates functions. All the business activity of the firm is functioned through the geographical regions of The United States.

Share on Social Networks: